John P. Lynch, M.D., Ph.D.
Assistant Professor of Medicine
Department: Medicine
Graduate Group Affiliations
Contact information
650 Clinical Research Building
415 Curie Blvd
Philadelphia, PA 19104
415 Curie Blvd
Philadelphia, PA 19104
Office: 2158980155
Fax: 2155732024
Fax: 2155732024
Email:
lynchj@mail.med.upenn.edu
lynchj@mail.med.upenn.edu
Publications
Education
B.A. (Chemistry)
University of Pennsylvania , 1987.
MD, PhD
University of Connecticut, 1994.
B.A. (Chemistry)
University of Pennsylvania , 1987.
MD, PhD
University of Connecticut, 1994.
Post-Graduate Training
Medicine, University of Pennsylvania School of Medicine, 1997-2000.
Medicine, Hospital of the University of Pennsylvania, 1994-1995.
Gastroenterology, Hospital of the University of Pennsylvania, 1996-2000.
Medicine, Hospital of the University of Pennsylvania, 1995-1996.
Permanent linkMedicine, University of Pennsylvania School of Medicine, 1997-2000.
Medicine, Hospital of the University of Pennsylvania, 1994-1995.
Gastroenterology, Hospital of the University of Pennsylvania, 1996-2000.
Medicine, Hospital of the University of Pennsylvania, 1995-1996.
Description of Research Expertise
Research InterestsCoordination of development and proliferation in the intestinal crypt and its dysregulation in carcinogenesis.
Mechanisms of cell-cell adhesion, and its role in intestinal epithelial cell development.
Cdx modulation of beta-catenin transcriptional and cell-cell adhesion activity in intestinal cells.
Mechanisms of intestinal metaplasia of the esophagus and stomach.
Description of Research
Primary Focus:
Colon cancer is an important cause of cancer mortality. In the United States, over 150,000 people are newly diagnosed with this disease each year, and a third of them will ultimately die from their disease. Abnormal regulation of beta-catenin levels and function commonly occurs during colon carcinogenesis. beta-catenin is a multifunctional protein with known roles in enhancing proliferation, inhibiting intestinal cell differentiation and apoptosis, and regulating cell-cell adhesion, angiogenesis, and cell migration.
Dysregulation of beta-catenin can thus endow a cancer cell with many of the features necessary for colon carcinogenesis. The mechanisms by which normal intestinal cells regulate beta-catenin function, and by which cancer cells abrogate this regulation, are not understood.
The homeodomain transcription factor Cdx2 is a well-studied regulator of intestine-specific gene expression. It's role in promoting intestinal cell differentiation and regulating proliferation is recognized but the mechanism remains unknown. Our research has specifically investigated these processes. We found that expression of Cdx2 inhibited beta-catenin/TCF transcriptional activity.
Moreover, cancer cells were relatively resistant to Cdx2's effect on beta_catenin/TCF, when compared with it's homologue Cdx1. In addition, we have developed a cell culture system to model Cdx2 induction of a polarized, columnar cell morphology in human colonocytes. This effect requires a functioning E-cadherin/beta-catenin complex, and involves post-translation modifications of beta-catenin. Current research is focused on characterizing the proliferation and cell-adhesion effects of Cdx2 on intestinal epithelial and cancer cells. Specifically we are testing the following hypothesis: Cdx2 inhibits colonocyte proliferation and promotes morphologic maturation by modulating beta-catenin transcriptional and cell-cell adhesion activity. Our work therefore explores a possible role for Cdx2 in regulating the interdependent processes of cell-cell adhesion, acquisition of a polarized and columnar morphology, and cell-proliferation within the colonocyte.
Understanding these mechanisms will greatly improve our knowledge of the events occurring normally in colonic crypts as well as enhance our understanding of the events leading to dysregulation of proliferation and differentiation in human colon cancers.
Secondary Focus:
Esophageal adenocarcinoma (EAC) has been the fastest rising malignancy in the U.S.. Several conditions increase the risk for the development of EAC, including obesity, smoking, diet, acid reflux, and, most significantly, Barrett's esophagus (BE). BE occurs at the gastroesophageal (GE) junction and is the replacement of normal squamous esophageal mucosa with an intestinalized columnar epithelium. It typically arises in response to chronic acid exposure and is associated with acid reflux. Importantly, the molecular mechanisms underpinning the establishment of Barrett's metaplasia are not understood. Moreover, no experimental cell-culture or animal models exist for this condition. Ectopic expression of intestine-specific transcription factors is characteristic of BE. The homeodomain transcription factor Cdx2 is an important regulator of intestine-specific gene expression. It is expressed ectopically in BE, but its role is unknown. Our research has investigated this role. We hypothesize that ectopic Cdx2 expression synergises with acid reflux, COX-2 overexpression, tumor-suppressor p53 mutations, and/or alterations in DNA methylation patterns to promote intestinal transdifferentiation of keratinocytes. We will test this hypothesis by developing cell-culture and transgenic mouse models for intestinal metaplasia.
Rotation projects for 2006-2007
Mechanisms of beta-catenin inhibition by Cdx2--biochemical and mutagenesis approaches
Cell-cell adhesion induced by Cdx2 in colon cancer cells--cadherins, desmocollin, and integrins
Animal and cell culture models of Barrett's metaplasia
Lab personnel:
Rong Jun Guo MD PhD--Post Doc
Jianping Kong PhD--Post Doc
Sanjay Hegde MD-Post Doc
Shinsuke Funakoshi MD-Visiting Scholar
Hong Li--Research specialist
Hoeun Lee-Technician
Selected Publications
Xiao F, Crissey MS, Lynch JP, Silberg DG, Suh E.: Intestinal Metaplasia with a High-Salt Diet InducesEpithelial Proliferation and Alters Cell Composition in the Gastric Mucosa of Mice. Cancer Biol Ther. Epub, 6(4): 669-75, June 2005.Guo RJ, Ezaki T, Suh ER, Lynch JP.: Cdx1 expression inhibitsB-catenin/TCF transcriptional Activity in Human Colon Cancer Cells. American Gastroenterological Association Annual Meeting 2005 Notes: Chicago, IL. May 2005.
Guo RJ, Huang E, Ezaki T, Patel N, Sinclair K, Wu J, Klein P, Suh ER, Lynch JP.: Cdx1 inhibits human colon cancer cell proliferation by reduccing b-catenin/TCF transcriptional activity. Journal of Biological Chemistry, 27 35(279): 36865-75, August 2004.
Keller, M., Ezaki, T., Guo, R-J., Lynch, J.P.: Cdx1 or Cdx2 Expression Activates E-Cadherin-mediated Cell-cell Adhesion and Compaction in Human Colo 205 cells. Am J Physiol Gastrointest Liver Physiol. 1(287): G104-114 2004.
Ezaki T, Guo RJ, Lynch JP.: Transcription factors Cdx1 or Cdx2 activate cell-cell adhesion by reducing B- and p120-catenin tyrosine phosphorylation. American Society for Cell Biology Annual Meeting 2004 Notes: Washington, DC. December 2004.
Guo RJ, Ezaki T, Suh ER, Lynch JP.: Cdx1 expression inhibits B-catenin/TCF transcriptional activity in human colon cancer cells. American Gasteroenterological Association Annual Meeting 2004 Notes: New Orleans, LA. May 2004.
Huang E, Guo RJ, Suh ER, Lynch JP: Cdx1 inhibits colon cancer cell proliferation by inhibiting B-catenin/TCF transcriptional activity. American Association for Cancer Research Annual Meeting 2004 Notes: Orlando, FL.
Guo RJ, Huang E, Ezaki T, Klein P, Fogt F, Lynch JP.: Homeodomain Transcription Factors Cdx1 and Cdx2 Inhibit Colon Cancer Cell Proliferation by Inhibiting B-catenin/T-cell Factor Trancriptional Activity. Jackson Laboratories Conference: Colon Cancer in Murine Models and Humans 2004 Notes: Bar Harbor, MA. September 30th-October 3rd, 2004.
Lynch, J.P., Keller, M., Guo, R-J.,Suh, E.R.,Yang, D., Traber, P.G.: Cdx1, a homeodomain transcription factor, inhibits proliferation of human colon cancer cells by reduction of cyclin D1 expression. Oncogene(22), 6395-6407, 2003.
Lynch, J.P., Hoops, T.C.: The Genetic Pathogenesis of Colorectal Cancer. Hematology/Oncology Clinics of North America(16), 1-36 August 2002.


